| Document |
Document Title |
|
WO/2007/002557A1 |
The present invention encompasses compounds of Formula (I): as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and meth...
|
|
WO/2007/002109A2 |
Provided herein are chelating agents and metal chelates that are useful in diagnostic and therapeutic applications. The uses of metal chelates provided herein include their use as contrast agents in medical imaging modalities, such as ma...
|
|
WO/2006/134124A1 |
A method for synthesising a compound having the general formula (I) wherein R represents substituents selected independently from the group of H, F, Cl, Br, NO2, alkyl, aryl, aralkyl, alkoxy, aryloxy, aralkoxy and disubstituted amine R' ...
|
|
WO/2006/134955A1 |
A compound represented by the general formula (1) or (100), a salt thereof or a hydrate of the compound or salt, which is excellent in cell adhesion-inhibitory effect and cell infiltration-inhibitory effect: (1) (100) wherein R10 represe...
|
|
WO/2006/130994A1 |
The syntheses and in vitro antitumor properties of carbamate-containing, dicarbamate-containing, and ureido-containing phospholipid compounds that have an ether linkage at the C-1 position of a glycerol backbone, a carbamate, dicarbamate...
|
|
WO/2006/132030A1 |
A compound represented by the following formula (I), which is useful as a reagent with which the concentrations of a peptide and a protein can be efficiently and easily determined with high sensitivity; and a method of analysis in which ...
|
|
WO/2006/132442A1 |
Disclosed are a compound represented by the general formula (I): (I) or a pharmaceutically acceptable salt thereof; a pharmaceutical composition comprising the compound or the like; and others. The compound or pharmaceutically acceptable...
|
|
WO/2006/127871A2 |
The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.
|
|
WO/2006/125550A1 |
The invention relates to methods for producing 2,5-disubstituted tetrahydropyranes from tetrahydropyran-3-ones, and to novel intermediates from these syntheses.
|
|
WO/2006/125529A1 |
The invention relates to formyltetrahydropyrans comprising mesogenic substituents, to a method for the production thereof and to the use thereof for producing substituted tetrahydropyran derivatives.
|
|
WO/2006/125688A1 |
The invention relates to benzoyl-substituted serine amides of formula (I), in which the variables R1 to R11 are defined as cited in the description and to their salts that can be used for agricultural purposes. The invention also relates...
|
|
WO/2006/125526A1 |
The invention relates to a method for producing the tetrahydropyran derivatives of formula (I), characterized by subjecting a tetrahydropyran derivative of formula (II) to a reductive elimination of substituent X1, whereby X1 represents ...
|
|
WO/2006/125530A1 |
The invention relates to a method for producing tetrahydropyrane derivatives which comprise at least one additional ring containing oxygen. The invention also relates to, in particular, compounds having two tetrahydropyrane rings or at l...
|
|
WO/2006/125527A1 |
The invention relates to a method for producing tetrahydropyran derivatives, to said tetrahydropyran derivatives and to the use of said tetrahydropyran derivative for producing other tetrahydropyran derivatives. The invention relates in ...
|
|
WO/2006/123355A2 |
The present invention provides novel statin derivatives and a facile process for preparation thereof selected from a group consisting of a compound of formula (I), wherein R is selected from a group consisting of -OH, -OR1, OCOR1, -OCHO,...
|
|
WO/2006/121095A1 |
A pharmaceutical composition comprising a compound having the general formula (I) or a pharmacologically acceptable salt thereof as the active ingredient: (I) wherein R1 represents a C6-C10 aryl group which may be substituted by a residu...
|
|
WO/2006/122020A2 |
The present invention relates to processes for the production of 4-biphenylylazetidin-2-one derivatives of formula (I).
|
|
WO/2006/121150A1 |
Disclosed are a novel (meth)acrylamide compound represented by the general formula (1) below, a (co)polymer of such a (meth)acrylamide compound, and a chemically amplified photosensitive resin composition composed of such a polymer and a...
|
|
WO/2006/119402A2 |
Compounds of the formula: (I) are described, along with pharmaceutical compositions containing these compounds, and methods of using the compounds to prevent and to treat cancer in mammals, including humans.
|
|
WO/2006/117360A1 |
The invention relates to crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4- ((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.
|
|
WO/2006/117359A1 |
The invention relates to a crystalline form of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((Sj-tetrahydrofura
n-3-yloxy)-benzyl]-benzene, to a method for the preparation thereof, as well as to the use thereof for preparing medicaments.
|
|
WO/2006/108802A1 |
Preparation of cyclic esters by hydrogenation of a carbonyl group in at least one anhydride radical -C(O)-O-C(O)- of a cyclic dicarboxylic or polycarboxylic anhydride by means of hydrogen in the presence of a homogeneous noble metal cata...
|
|
WO/2006/108591A1 |
The present invention relates to l H-Quinazoline-2,4-diones of formula (I) wherein R1 and R2 are as defined in the specification, their preparation, their use as AMPA-receptor ligands, in particular for the treatment of epilepsy or schiz...
|
|
WO/2006/104387A1 |
One aspect of the present invention is concerned with a composition containing: (A) at least 10 μg of particular substituted pyrroles per kg of dry matter; and (B) at least 100 mg per kg of dry matter of a pyranone selected from the gro...
|
|
WO/2006/101144A1 |
[PROBLEMS] To provide a charge control agent, which has a practical level of negative charge imparting properties, is colorless and a light color and can be used in a color toner, can realize good stability against an environmental chang...
|
|
WO/2006/100100A1 |
The invention relates to tetrahydronaphthalene derivatives of general formula (I), to a method for their production and to their use as anti-inflammatory agents.
|
|
WO/2006/098959A1 |
The present invention is concerned with novel processes for the preparation of (R)-4,4-dimethoxy–pyran-3-ol. This compound is useful as an intermediate in the synthesis of compounds which possess pharmacological activity including CCR2...
|
|
WO/2006/098308A1 |
An anthranilic acid derivative represented by the general formula below or a salt thereof: wherein R1 and R2 independently represent a hydrogen atom or the like; R3 represents a phenyl, cycloalkyl or bicyclic heterocyclic group which may...
|
|
WO/2006/095475A1 |
[PROBLEMS] To provide a compound which has a satisfactory catalytic activity for use as a catalyst carrying a metal belonging to the chromium group therein, which can be separated from a desired product readily and which is reusable. [ME...
|
|
WO/2006/095020A1 |
Compounds of the general formula (I) in which the meanings of the substituents R1 and R2 are as stated in claim 1, have renin-inhibiting properties and can be used as medicines.
|
|
WO/2006/093336A1 |
Disclosed is a fibronectin gene transcription inhibitor composition or the like characterized by containing a cinnamoyl compound represented by the formula (I) below and an inert carrier. (I)
|
|
WO/2006/092049A1 |
The invention comprises compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions containing the compounds or prodrugs of the compounds. The invention also comprises animal models and m...
|
|
WO/2006/089872A1 |
Glucopyranosyl-substituted (hetero)arylethynyl-benzene derivatives of the general formula (I) where the groups R1 to R6 as well as R7a, R7b, R7c are defined according to claim 1, including the tautomers, the stereoisomers thereof, the mi...
|
|
WO/2006/089008A2 |
The present invention relates to methods for the preparation of 3,3-dialky 4- chromanones, and particularly to the preparation of 6-fluoro-3,3-dimethyl-2,3-dihydro- 4H-chromen-4-one and 3,3-dimethyl-2,3-dihydro-4H-chromen-4-one. In some ...
|
|
WO/2006/085510A1 |
A remedy for IBS comprising, as the active ingredient, a dual antagonist for 5-HT2B and 5-HT7 receptors which shows selective binding affinities to 5-HT2B and 5-HT7 receptors. The above-described medicinal composition is superior in the ...
|
|
WO/2006/083271A2 |
The invention provides certain acylthiourea derivatives and pharmaceutically acceptable salts thereof. These compounds possess potent antiviral activity. The invention particularly provides compounds that are potent and/or selective inhi...
|
|
WO/2006/082594A1 |
An improved method for manufacture of simvastatin of formula (I) in high purity. The process for preparation of compound (I) comprises Formula I the steps of agitating a compound of formula (II), Formula II wherein R is hydrogen, NH4+ or...
|
|
WO/2006/082010A1 |
Provided herein are compounds of the formula (I), as well as pharmaceutically acceptable salts thereof, wherein R1, R2, R2´, R3, R4, R5 and X are as defined in the specification and claims. These compounds, and the pharmaceutical compos...
|
|
WO/2006/080339A1 |
A process for producing 5-chloro-2,4-dihydroxypyridine of Formula (1) comprising the steps of reacting a 5-chloro-1,3-dioxin-4-on derivative (2) represented by Formula (2) with a ketene acetal derivative (3) represented by Formula (3) to...
|
|
WO/2006/072963A1 |
The application describes a new process for preparing Simvastatin from Lovastatin amine salts in three steps. Lovastatin was hydrolysed to acid form and then isolated in the form of amine salt like cyclopropyl or t-octyl amine etc. The s...
|
|
WO/2006/070383A1 |
The present invention relates to a process for the synthesis of racemic nerol oxide i.e. 3,6-dihydro-4-methyl-2-[2-methyl-1-propenyl)-2H-pyran from monoterpene alcohol nerol i.e. cis-3,7-dimethylocta-2,6-diene-1-ol.
|
|
WO/2006/068213A1 |
A glycine derivative which is, e.g., the following compound (Chemical formula (1)). It is highly effective in the treatment and prevention of inflammatory bowel diseases. Compared to conventional compounds, the compound is excellent in a...
|
|
WO/2006/064179A1 |
There is provides a process for the preparation of a compound of formula (7): wherein R is an optionally substituted hydrocarbyl group or an optionally substituted heterocyclic group; provides that R is not a compound of Formula (a): whe...
|
|
WO/2006/062110A1 |
A compound represented by the formula (I): [wherein R1 represents C3-9 branched alkyl; R2 represents, e.g., linear or branched, C2-9 alkyl optionally substituted by halogen, etc.; and X represents oxygen, etc.] (provided that the followi...
|
|
WO/2006/062211A1 |
The invention provides a production process of a tetrahydropyran compound, characterized by allowing 3,4-dihydro-2-alkoxy-2H-pyran compound or tetrahydro-2-alkoxy-2H-pyran compound which can be easily prepared through reaction between ac...
|
|
WO/2006/059346A2 |
This invention describes a process for lactonization of simvastatin hydroxyacid or its salts that avoids use of strong corrosive acids and drastic heat conditions. Specifically the process can be carried out at moderate temperature resul...
|
|
WO/2006/055472A2 |
Synthetic discodermolide analogs having utility as antiproliferative agents, having a structure represented by formula A, where RA through RE and XA are as difined herein.
|
|
WO/2006/054688A1 |
A process for producing tetrahydropyran-4-carboxylic acid of the formula: (1) characterized by hydrolytic reaction, in the presence of an acid, of a 4-cyanotetrahydropyran-4-carboxylic acid compound of the formula: (2) wherein R is a hyd...
|
|
WO/2006/045554A1 |
The present invention relates to compounds having the general formula (I) with the definitions of A, X, R1-R6 given below, and/or a salt or ester thereof. Furthermore the invention relates to the use of said compounds for the treatment o...
|
|
WO/2006/038522A1 |
Liquid crystal compounds having general physical properties necessary to compounds, low viscosity, proper optical anisotropy, proper anisotropy of permittivity, and excellent compatibility with other liquid crystal compounds; liquid crys...
|
